Pancreatic masses are routinely seen on abdominal imaging. Patients with pancreatic masses often present with non-specific clinical presentation, making pre-operative imaging an essential tool in their management. The imaging modalities available for assessment of pancreatic masses may be invasive or non-invasive. Non-invasive modalities include abdominal ultrasonography, CT, MRI and MRCP, PET imaging, hybrid PET-CT. Invasive modalities include Endoscopic ultrasound and ERCP. We propose to attend these objectives: To delineate spectrum of imaging findings in Pancreatic masses. Elucidate role of MDCT and Endoscopic ultrasound (EUS) in...

Pancreatic masses are commonly encountered and are a diagnostic challenge on imaging modalities. One of the most common cystic lesions of the pancreas include pancreatic pseudocysts which require treatment, some pancreatic cystic lesions require only imaging follow up, whereas some pancreatic cystic lesions are of malignant etiology and ask for aggressive treatment. Solid masses can range from benign inflammatory masses to malignant masses and may present with similar clinical presentation and their differentiation dictates the appropriate management strategies. Clinically patients with Pancreatic masses may be...

1) Dual Phase CT of the abdomen using pancreatic protocol with image acquisition at 35-40 seconds after I.V. contrast corresponding to pancreatic parenchymal phase 65-70 seconds after I.V. contrast corresponding to portal venous phase 2) Endoscopic Ultrasound (EUS) using linear echoendoscope of 5-13 Mhz under mild sedation.Endoscopic Ultrasound guided FNAC/Cyst aspiration using 22G echotip needle whereverindicated. PANCREATIC ADENOCARCINOMA Pancreatic ductal adenocarcinomas constitute the most common primary malignant tumor, accounting for 85%-95% of all pancreatic malignancies and is also the fourth leading cause of cancer related...

MDCT performed using pancreatic protocol is the first line imaging modality for evaluation of suspected pancreatic mass. Hypo-enhancing solid masses with extensive SMA , celiac trunk or SMV involvement and distant metastases tend to be unresectable pancreatic adenocarcinomas. EUS is beneficial in detection of masses <2cm in size, or causing mild pancreatic contour deformity on CT and for guiding FNAC or aspiration of cystic lesions.

Irie H, Honda H, Kaneko K, Kuroiwa T, Yoshimitsu K, Masuda K. Comparison of helical CT and MR imaging in detecting and staging small pancreatic adenocarcinoma. Abdom Imaging. 1997 Jul-Aug;22(4):429-33. Varadhachary GR, Tamm EP, Crane C, Evans DB, Wolff RA. Borderline resectable pancreatic cancer. Current treatment options in gastroenterol. 2005;8:377-84. Evans DB, Wolff RA, Crane CH. Neoadjuvant Strategies for Pancreatic cancer. Oncology. 2001;15(6):727-747. Pieteryga JA, Morgan DE. Imaging preoperatively for pancreatic adenocarcinoma. J Gastrointest Oncol. 2015; 6(4):343-357. Scatarige JC, Horton KM, Sheth S, Fishman EK....